Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript
Welcome back, everyone, to the 2023 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotech equity research analysts here at RBC. And we're pleased to be joined for this session by Verastem.
Joining us from the company is the Chief Executive Officer, Brian Stuglik; and the Chief Scientific Officer, Jon Pachter. So it's great to have you guys.
Questions & Answers
Brian, I think I just wanted to just start by having you give us a brief overview of Verastem -- a great deal going on. Many folks are familiar with the name of the company, but there are some interesting developments with your lead asset. And I think bringing investors up to speed is worthwhile.
Yeah, sure. Great. Thanks, Greg. So several years ago, we pivoted the company. We started with the product -- our company was founded on a product called defactinib back in 2012. And again, we did some
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
